Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

AETNA Inc. Issues Positive Coverage Decision for ThyroSeq® Thyroid Genomic Classifier

ThyroSeq
Posted on: 10 Jan 18
AETNA Inc. Issues Positive Coverage Decision for ThyroSeq® Thyroid Genomic Classifier The Highly Accurate Test Provides Better Treatment Options For Aetna Insurance Plan Members

PR Newswire

NEW YORK, Jan. 10, 2018

NEW YORK, Jan. 10, 2018 /PRNewswire/ -- ThyroSeq®, a joint partnership between UPMC and Sonic Healthcare USA, announced that Aetna has issued a positive coverage decision for ThyroSeq Thyroid Genomic Classifier.  Aetna and its more than 19 million members will now have access to ThyroSeq's highly accurate test which will result in better treatment options for patients with thyroid nodules and decrease a significant number of avoidable diagnostic thyroid surgeries.

"We are excited about the positive coverage decision and that Aetna's members will now be able to benefit from access to the ThyroSeq test," said Yuri Nikiforov, M.D., Ph.D., Professor of Pathology at University of Pittsburgh Medical Center, and principle of ThyroSeq. "The use of this test will prevent the largest number of avoidable thyroid surgeries and help to apply more individualized management to patients with thyroid nodules and cancer based on the cutting-edge genomic science." 

"This positive coverage decision for ThyroSeq Genomic Classifier by Aetna fits hand in hand with Sonic Healthcare's commitment to high quality patient care," says Jerry Hussong M.D., Chief Medical Officer of Sonic Healthcare USA.

ThyroSeq's V3® is an effective tool for a definitive diagnosis in thyroid nodules that have indeterminate fine-needle aspiration cytology, enabling the most cost-effective patient care. ThyroSeq V3 has both very high sensitivity and high specificity and therefore can be used as a "rule-out" and "rule-in" test for cancer in thyroid nodules. ThyroSeq V3 provides additional valuable prognostic information, informing the most optimal, personalized surgery for cancerous nodules.

About ThyroSeq®
ThyroSeq is a joint partnership between UPMC and Sonic Healthcare. ThyroSeq is an innovative test for thyroid nodules and cancer. With a 10-year history of continuous refinement, it incorporates all major scientific discoveries and utilizes advanced technology to provide the most accurate diagnosis of benign or malignant disease in thyroid nodules. For more information, visit ThyroSeq.com.

About Sonic Healthcare
Sonic Healthcare is one of the world's largest medical diagnostics companies. It provides comprehensive laboratory medicine/pathology services to healthcare professionals within private and public medical communities and to commercial enterprises. Headquartered in Sydney, Australia, Sonic has grown to become one of the world's leading healthcare providers with operations in USA, Australia, Germany, Switzerland, United Kingdom, Belgium, Ireland and New Zealand. Sonic's unwavering commitment is driven by the leadership team, dedicated to its patients' health and physician clients' success. For more information, please visit SonicHealthcare.com.

MEDIA CONTACT
Jeanine Wilson
(845) 548-1211
thyroseq@wmediagroup.com

View original content with multimedia:http://www.prnewswire.com/news-releases/aetna-inc-issues-positive-coverage-decision-for-thyroseq-thyroid-genomic-classifier-300580855.html

SOURCE ThyroSeq

PR Newswire
www.prnewswire.com

Last updated on: 10/01/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.